AIAISci
中文
clinical updateBiotech

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Clinical/translation signal: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Occurred SourceClinicalTrials.govapprovedSourceClinicalTrials.gov

Factual summary

What happened

ClinicalTrials.gov registry update for Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

SourceClinicalTrials.gov

Why it matters

Clinical trial registry updates are translation signals, not commercialization claims by themselves.

SourceClinicalTrials.gov

Limitations

ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.

SourceClinicalTrials.gov

Linked output

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)clinical trial

People

No reviewed person relationship is attached to this event.

Organizations

National Cancer Institute (NCI)

Topics

No reviewed topic relationship is attached to this event.

Problems

No reviewed problem relationship is attached to this event.

Relationship evidence

Timeline

  1. clinical updateNeoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
    SourceClinicalTrials.gov